팝업레이어 알림

caec085f813e6402c9521f6cb02318cd_1567991037_368.png
 

ABOUT US

Site-agnostic cancer diagnosis solutions for powering the latest breakthrough cancer clinical investigations

Current site-dependent cancer diagnostic tools are insufficient in meeting the needs of the newest paradigm of site-agnostic treatments in oncology. Biogemex is an innovative diagnostics company focused on developing the site-agnostic cancer diagnosis solutions for accelerating the breakthrough clinical investigations of cancer immunotherapies and site-agnostic precision drugs.

Innovations and experience built on sustainability

At Biogemex, we believe that maturity, experience, and stability are the foundation to a successful biotech development. Through early incorporation of revenue generating pipelines in the segments of pregnancy diagnostic kits, Biogemex has established the sustainability and the experience of manufacturing and development for propelling our innovations.

SITE-AGNOSTIC CANCER DIAGNOSIS

Site-agnostic cancer diagnosis technology for powering the site-agnostic cancer treatments

In healthy state, immunity kills and controls cancer throughout our body from head to toe. And the 2018 Nobel Prize-winning cancer immunotherapy drugs called checkpoint inhibitors proved that our immunity can be used in treating over 48% of all cancer cases throughout our body (Haslam and Prasad, 2019). Coined “site-agnostic” treatment, this new paradigm of immunity-based cancer treatment works independent of the anatomical location of cancer and results in cure if successful.

With continuing developments in cancer immunotherapy, medicine is approaching the idea of curing cancer of any locations without surgical intervention. And in this nearing future, early and successful diagnosis of cancer or its metastasis itself is the most important concern, rather than the determination of its anatomical location.

Based on the proven science of PKA Cα autoantibody for pan-cancer diagnosis (Nesterova et al., 2006; Cho 2006; Cho et al., 2000), Biogemex is delivering the very future: site-agnostic cancer diagnosis for powering site-agnostic cancer treatments. Successful translation of our technology will be instrumental in accelerating and improving the fidelity of the ongoing immunotherapy clinical investigations against metastatic breast cancer, ovarian, or prostate cancer among others.

BioGemex is focusing on the development of point-of-care (POC) diagnostic kit to detect PKA Cα autoantibody which can be conducted by TumorScreen. Thus, TumorScreen will be the first site-agnostic diagnosis for powering the latest breakthrough cancer clinical investigations.

Different expression of PKA C α autoantibody

Comparison of conventional and BGX’s novel biomarkers

Conventional individual cancer diagnosis BGX’s pan-cancer diagnosis
Cancer type Cancer-specific Pan-cancer monitoring
Detection method Mostly qualitative Quantitative
Biomarker Mostly antigen Autoantibody
Accuracy Low specificity and High sensitivity High specificity and sensitivity (tested via ELISA)
(will be validated with POC diagnostic, the TumorScreen)
Early cancer detection (Y/N) N Y

Site-agnostic Cancer Diagnostics Pipelines

Tests and Assays planned for 2019 - 2020

Product name Biomarker Detection methods(Status) Indication in development
TumorScreen Anti- PKA Cα antibody ELISA & Rapid High priority targets: ovarian cancer, prostate cancer, breast cancer
TumorScreen (Ver2) Anti- PKA Cα antibody combination with other universal cancer biomarkers Preclinical Various cancers

Instruments/devices planned for 2019 -2021

Product name Description
TumorScreen single reader Quantification of Anti- PKA Cα antibody
BG product semi/full automation Automation reader system to conduct BG’s diagnostic test series

Business

#3, 620, Samseong-ro, Gangnam-gu, Seoul,06085, Korea

TEL : +82-70-5096-5936

FAX : +82-2-569-7644

EMAIL : business@biogemex.com

R&D

#317, Hyundai I-Valley, 31, Galmachi-ro 244beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, 13212, Korea

TEL: +82-70-7753-2260

FAX : +82-31-737-9806

EMAIL: rnd@biogemex.com

Manufacture

#318, Hyundai I-Valley, 31, Galmachi-ro 244beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, 13212, Korea

TEL : +82-31-737-9800

FAX : +82-31-737-9806

EMAIL : manufacture@biogemex.com